Back to top
more

Intuitive Surgical (ISRG)

(Real Time Quote from BATS)

$471.04 USD

471.04
754,939

+0.96 (0.20%)

Updated Aug 11, 2025 03:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 39% (148 out of 244)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Becton, Dickinson Ties Up With Helmer Scientific to Boost MMS

by Zacks Equity Research

Becton, Dickinson (BDX) aims to boost its MMS segment through the promotion of its Pyxis ES refrigerator.

    Zacks Equity Research

    Here's Why You Should Sell Cardinal Health (CAH) Stock Now

    by Zacks Equity Research

    Cardinal Health (CAH) faces sluggishness in the exam-gloves unit lately. Further, cutthroat competition in the niche space is a headwind.

      Zacks Equity Research

      Here's Why You Should Buy Abiomed (ABMD) Stock Right Now

      by Zacks Equity Research

      Abiomed's (ABMD) solid Impella product line and the inclusion in the S&P 500 connect make it a lucrative pick.

        Zacks Equity Research

        Amedisys (AMED) Buys Back 2.4M Shares From KKR, Stock Up

        by Zacks Equity Research

        Amedisys (AMED) works on its strategy to deploy capital in an accretive manner, maintaining low leverage and substantial borrowing capacity for future investment.

          Zacks Equity Research

          Medtronic's (MDT) CRHF Arm Growth Strong, Rising Costs a Woe

          by Zacks Equity Research

          The gradually stabilizing Cardiac Rhythm & Heart Failure (CRHF) market increases investor confidence in the Medtronic (MDT) stock.

            Zacks Equity Research

            NuVasive's (NUVA) Global Prospects Solid, Competition Rife

            by Zacks Equity Research

            NuVasive (NUVA) demonstrates strong sales growth across all geographies. Competitive landscape is a concern.

              Zacks Equity Research

              Here's Why You Should Invest in Stryker (SYK) Stock Now

              by Zacks Equity Research

              Stryker's (SYK) focus on inorganic expansion and stellar Mako performance make the stock an attractive buy.

                Zacks Equity Research

                Boston Scientific Grows on New Products Amid Recall Issues

                by Zacks Equity Research

                Boston Scientific's (BSX) 2018 guidance raises optimism for the company's near-term prospects.

                  Zacks Equity Research

                  Bruker Unveils New Mass-Spectrometry Products, Boosts CALID

                  by Zacks Equity Research

                  Bruker's (BRKR) mass-spectrometry business within its CALID group rides high on strong sales performances in recent times.

                    Zacks Equity Research

                    4 Medical Device Stocks with Solid Potential to Buy Now

                    by Zacks Equity Research

                    The Medical Device tax suspension spells good times for MedTech bigwigs.

                      Zacks Equity Research

                      Abbott Launches Afinion 2 Analyzer Rapid Test in the U.S.

                      by Zacks Equity Research

                      Abbott's (ABT) recently-launched Afinion 2 analyzer system is likely to boost top-line contributions from the Diagnostic division.

                        Zacks Equity Research

                        Illumina (ILMN) Grows on Innovation & Strategic Partnerships

                        by Zacks Equity Research

                        Illumina's (ILMN) alliances with Bristol-Myers Squibb and Loxo Oncology to reap positive results in oncology.

                          Zacks Equity Research

                          Here's Why You Should Invest in Baxter International Now

                          by Zacks Equity Research

                          Strategic buyouts consistently help Baxter (BAX) gain market traction. Recently, the company completes the consolidation of both RECOTHROM and PREVELEAK.

                            Zacks Equity Research

                            Here's Why You Should Invest in PerkinElmer (PKI) Stock Now

                            by Zacks Equity Research

                            PerkinElmer (PKI) gains from stellar Q1 performance; a raised guidance holds promise.

                              Zacks Equity Research

                              Is Intuitive Surgical (ISRG) Stock Outpacing Its Medical Peers This Year?

                              by Zacks Equity Research

                              Is Intuitive Surgical, Inc. (ISRG) Outperforming Other Medical Stocks This Year?

                                Zacks Equity Research

                                ResMed's (RMD) HEALTHCAREfirst Buyout to Boost SaaS Business

                                by Zacks Equity Research

                                Integration of HEALTHCAREfirst's solutions suite with ResMed's (RMD) SaaS portfolio will help manage the burgeoning population and provide benefits to patients.

                                  Nabaparna Bhattacharya headshot

                                  US-North Korea Summit Talks Resume: 4 MedTech Stocks to Watch

                                  by Nabaparna Bhattacharya

                                  Here we take a look at four leading MedTech players that are gaining from opportunities in the APAC market

                                    Zacks Equity Research

                                    Intuitive Surgical Commences Direct Operations in India

                                    by Zacks Equity Research

                                    Intuitive Surgical (ISRG) looks to install a broader base of its flagship da Vinci surgical system through distributor Vattikuti in India.

                                      Zacks Equity Research

                                      Here's Why You Should Add ResMed (RMD) to Your Portfolio Now

                                      by Zacks Equity Research

                                      With a view to consistently lead the SDB market and boost the company's sales, ResMed (RMD) sets sights on product development and innovation.

                                        Zacks Equity Research

                                        Here's Why STERIS (STE) Stock is a Must Buy at the Moment

                                        by Zacks Equity Research

                                        STERIS (STE) gains ground on strategic buyouts and divestments.

                                          Zacks Equity Research

                                          Myriad Genetics' Planned Counsyl Buyout to Widen Portfolio

                                          by Zacks Equity Research

                                          Myriad Genetics (MYGN) plans to retain Counsyl as a wholly-owned subsidiary post the successful completion of the acquisition.

                                            Zacks Equity Research

                                            IDEXX's (IDXX) Catalyst Uptake Remains Strong & Boosts CAG

                                            by Zacks Equity Research

                                            Solid organic growth trend within IDEXX's (IDXX) CAG revenues to sustain on the back of a strong global placement of high-premium Catalyst instruments.

                                              Zacks Equity Research

                                              Abbott Presents Positive Data for AMPLATZER Amulet Device

                                              by Zacks Equity Research

                                              Abbott (ABT) proceeds with initiatives to boost the core Structural Heart division.

                                                Zacks Equity Research

                                                Merit Medical (MMSI) Up 18.9% in a Month on Solid Q1 Earnings

                                                by Zacks Equity Research

                                                Merit Medical (MMSI) reports strong Q1 earnings and sees solid growth across segments and geographies.

                                                  Zacks Equity Research

                                                  Quality Systems (QSII) Q4 Earnings Beat, Bookings Rise Y/Y

                                                  by Zacks Equity Research

                                                  Quality Systems (QSII) exits fourth quarter on a solid note with a surge in bookings; issues a solid guidance for fiscal 2019.